{"id":2357,"date":"2025-03-04T11:45:56","date_gmt":"2025-03-04T03:45:56","guid":{"rendered":"https:\/\/www.kousai.vip\/?p=2357"},"modified":"2025-03-06T13:45:05","modified_gmt":"2025-03-06T05:45:05","slug":"%e6%81%92%e8%b5%9b%e7%94%9f%e7%89%a9dc%e7%96%ab%e8%8b%97%e6%b2%bb%e7%96%97%e8%82%be%e7%99%8c%e9%a1%b9%e7%9b%ae%e6%ad%a3%e5%bc%8f%e5%90%af%e5%8a%a8","status":"publish","type":"post","link":"https:\/\/www.kousai.vip\/en\/2025\/03\/%e6%81%92%e8%b5%9b%e7%94%9f%e7%89%a9dc%e7%96%ab%e8%8b%97%e6%b2%bb%e7%96%97%e8%82%be%e7%99%8c%e9%a1%b9%e7%9b%ae%e6%ad%a3%e5%bc%8f%e5%90%af%e5%8a%a8\/","title":{"rendered":"Hengsai Bio DC Vaccine for Kidney Cancer Program Officially Launched"},"content":{"rendered":"
\n
\n
\n
\n

On March 3, 2025, Hengsai Bio's self-developed KSD-201 DC vaccine for the treatment of advanced renal cell carcinoma was formally launched at Tongji Hospital of Huazhong University of Science and Technology Tongji Medical College (\"Wuhan Tongji Hospital\").<\/strong>Relying on Hengsai Bio's world-leading Eco-DC Vax technology platform and in collaboration with a team of urology experts from Wuhan Tongji Hospital, the project aims to provide a novel immunotherapy solution for patients with relapsed and refractory kidney cancer. This is another solid tumor pipeline of Hengsai Biotech that has entered clinical research after EBV-related nasopharyngeal carcinoma.<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

The scene of the launch event<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

The Department of Urology of Wuhan Tongji Hospital, as one of the \"Top 10 Urological Tumors in China\", has a leading position in the field of minimally invasive surgery and individualized comprehensive treatment of renal cancer by its multidisciplinary team (MDT). Renal cell carcinoma (RCC) is a malignant tumor originating from the epithelium of renal tubules, accounting for about 85% of renal malignancies. clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of RCC. ccRCC has the poorest prognosis of all the pathologic types of RCC, with the highest recurrence and metastatic potential, and it is insensitive to both radiotherapy and chemotherapy. Advanced ccRCC is an incurable disease, prone to metastasis, recurrence, and refractory to eradication, with marked individualized differences in efficacy and survival benefit of targeted therapies, severe adverse effects, and easy drug resistance. Therefore, ccRCC has always been a difficult problem for many patients, bringing a heavy burden to patients and their families.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

At the launching meeting, a team of urology experts headed by the principal investigator Prof. Wang Shaogang and the clinical team of Hengsai Biologicals discussed the focuses and difficulties of the IIT study of DC vaccine treatment for ccRCC disease, and both sides clarified the project objectives and division of labor between the two sides, showing high expectations and firm confidence in the future development of the project, which laid a solid foundation for the efficient promotion of the subsequent project.<\/p>\n\n\n\n

Dr. Huining Liu, Founder and CEO of Hengsai Biologics, said, \"The unique advantage of DC Vaccine lies in inducing long-term immune memory and exerting lasting anti-tumor effects through precise and specific immune responses. This collaboration with Wuhan Tongji Hospital will accelerate the translation of the technology from the laboratory to the clinic, and we look forward to DC Vaccine providing more kidney cancer patients with a safe, convenient and long-lasting effective treatment option.\"<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n